Depression drug may be cleared for children
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Children could soon be given the controversial anti-depressant drug Seroxat – despite evidence linking it to suicidal thoughts and mental problems in young teenagers.
In a move that will alarm the drug's critics, the British pharmaceuticals giant GlaxoSmithKline has asked for permission to market Seroxat to children in the United States. The application is expected to be followed by a similar bid in Europe.
Glaxo's decision comes despite evidence that its own clinical trials found that 10 per cent of depressed children who were given the drug endured serious psychiatric problems within weeks of using it.
Although the 93 children in the trial generally did better than those on an older drug or a placebo, five suffered suicidal thoughts, and five had other serious psychiatric problems. Many of the affected teenagers had to be sent to hospital.
These disclosures, to be made in a BBC Panorama documentary tonight, will deepen the controversy over the safety of Seroxat.
One of Britain's leading experts on anti-depressants, Dr Ian Healy, claims on Panorama that some doctors and psychiatrists are already giving children the drug, even though it is not officially approved for paediatric use.
The drug is now the world's second most popular anti-depressant, earning Glaxo £378m in European sales last year. Its critics allege Glaxo is keen to win approval to sell it for children partly because it will extend the patent giving it exclusive sales rights for a further six months.
The drug, sold in the US as Paxil, has been at the centre of a series of legal actions and claims that it causes suicidal tendencies, violence and depression among adult users.
Glaxo has already been ordered to pay one US family $6m (£3.9m) after a jury found that the drug led one 61-year-old man to kill his family of three and then himself by making him deranged.
But it won a major victory last week, when a judge in Los Angeles threw out one of the main charges against the drug, that it is also addictive.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments